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Clearing the Way or Ushering the Storm?*Michael R. Jaff, DOSEE PAGE 102W ith the overwhelming expansion of dia-betes mellitus across the world (1), it isof no surprise that peripheral artery dis-
ease (PAD) is now a worldwide health hazard (2).
With improved diagnostic methods and increasing
awareness, more patients are being considered for
revascularization strategies. Classically, revasculari-
zation in the form of surgical bypass was reserved
for patients with manifestations of critical limb
ischemia (rest pain, nonhealing ischemic ulcerations,
gangrene). With the rapid advances in minimally
invasive technologies over the past 2 decades, “endo-
vascular ﬁrst” strategies have become prevalent. As
one observes the evolution of devices from uncoated
percutaneous transluminal angioplasty (3), bare
nitinol stents (4), atherectomy (5), to drug-eluting
stents (6), optimism for our ability to improve func-
tional limitations and reduce the risk of limb loss
has increased.
The ability to coat a balloon angioplasty catheter
with an antiproliferative agent, however, has resulted
in tremendous anticipation and enthusiasm by in-
vestigators and clinicians alike as a potential primary
management of femoropopliteal PAD. This was
sparked by the initial publication of the THUNDER
(Local Taxan With Short Time Contact for Reduction
of Restenosis in Distal Arteries) trial (7). In this pilot
randomized trial, the primary endpoint of late lumen
loss (a measure adopted from percutaneous coronary
intervention trials) favored the balloon catheter
coated with a concentrated ﬁlm of paclitaxel. In this*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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vestigators extend the experience from the THUNDER
trial by reporting 5-year outcomes (8). The authors,
who represent some of the most important and
inﬂuential PAD investigators worldwide, continue to
expand our knowledge of the role of interventional
management in patients with symptomatic PAD.Only 2 of the 3 previously randomized arms in the
THUNDER trial were included in this analysis, repre-
senting 102 patients. Unfortunately, this follow-up
was not always performed with an in-person evalua-
tion, but rather via telephone assessments. This
immediately limits our ability to generalize these re-
sults to larger patient cohorts. In addition, formal
anatomic follow-up was not mandated in all patients
at 5 years, and therefore, only those patients who
actually had arteriography and/or duplex ultraso-
nography and could actually obtain those images
were analyzed. Independent core laboratories did not
interpret these images.
The authors do a commendable job of demon-
strating the consistent advantages of the drug-coated
balloon to bare balloon angioplasty, including a
reduction in late lumen loss, fewer target lesion re-
vascularizations (TLR), longer time periods from the
initial intervention to TLR, and despite the small
numbers and limitations of the analysis, improved
binary patency at 5 years. These impressive ﬁndings
were associated with no increase in adverse events,
including arterial toxicity, amputations, or mortality
rates.
The combination of devices and drugs for the
management of PAD appears to hold considerable
appeal for clinicians, researchers, and commercial
manufacturers alike (9). Although the results of drug-
eluting stents are superior to percutaneous trans-
luminal angioplasty (6), there remain concerns about
permanent implantable devices. Bioresorbable scaf-
folds hold tremendous hope (10); however, at least in
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110the peripheral artery segments, no large-scale trials
are near completion, and the early results are await-
ing peer-reviewed publication.
Drug-coated balloons, however, have been widely
available in Europe, and the ﬁrst trial data presented
to a U.S. Food and Drug Administration panel was
completed earlier this summer (11). Another large-
scale randomized trial presented its data at an inter-
national meeting in April 2014 (12). It is therefore
anticipated that drug-coated balloons will enter the
U.S. marketplace within the next 12 to 18 months.
The enthusiasm for drug-coated balloons rests with
the lack of a permanent implantable device, an anti-
proliferative agent to lessen restenosis, and the ability
to offer a full spectrum of revascularization strategies
should the initial intervention fail. With the recently
reported randomized data (still pending peer-
reviewed publication at the time this paper was writ-
ten) and the results of the THUNDER 5-year follow-up,
it appears that drug-coated balloons will have an
impact on the patients with PAD who require inter-
vention. One factor that will undoubtedly impact the
uptake of this class of technologies is the cost effec-
tiveness compared with other revascularization and
medical strategies. The data on this are quite limited
but suggest a potential advantage to payers because of
the low TLR rates of drug-coated balloons (13).
The 5-year THUNDER trial data unfortunately do
not shed light on the actual cost impact of the 2 armsreported. In addition, we have no insights into the
optimal drug, the optimal dose concentration of the
drug, effective adjuvant medical therapy, including
the role of antiplatelet therapy, cholesterol lowering,
and tobacco cessation. Finally, there remain no
comparisons of drug-coated balloons for treatment of
claudication as a result of femoropopliteal artery
disease to supervised exercise and optimal medical
therapy, as studied in iliac artery disease (14).
Are there lessons here? Undoubtedly. We need to
determine what endpoints for trials in patients with
claudication truly matter, and to which constituency.
Each trial must demonstrate objective functional
beneﬁts following intervention, as that is why patients
want these procedures—they choose to walk farther
with less discomfort. We are obligated, in this era of
accountable care, to measure episodes of care and
total medical expense, and consider comparative costs
and outcomes. We need to consider what is really cost
effective for the claudicant (15). If we don’t, I am afraid
that the THUNDER we hear will not represent
advancing data but rather, doors closing to adoption of
new technologies and outcomes by payers, ultimately
limiting options for our PAD patients.
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